Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Common Arthritis Supplements Have No Effect

September 17, 2010 7:57 am | News | Comments

European researchers analyzed the results of 10 past trials in 3,803 patients who took glucosamine, chondroitin or a placebo to treat arthritis in their hips or knees. They found neither supplement, taken either separately or together, did any better than a placebo.


J & J to Acquire Crucell

September 17, 2010 7:53 am | by Toby Sterling | News | Comments

Johnson & Johnson said it is in advanced talks to acquire Dutch biotech firm Crucell NV for €1.75 billion ($2.29 billion), a deal that would boost the American health care product maker's vaccine business.


A New Way to Manage Cardiometabolic Risk Associated with Diabetes and Pre-diabetes

September 17, 2010 6:08 am | by Rémy Hanf, PhD, Vice President of Product Development; GENFIT, Lille, France | Articles | Comments

Cardiometabolic disorders represent a combination of cardiometabolic risk factors including elevated fasting glucose, elevated triglycerides, low HDL-cholesterol levels, abdominal obesity, and hypertension.


CHO Cell Lines

September 16, 2010 8:51 am | Drug Discovery & Development | Product Releases | Comments

Life Technologies Corporation announced that it has finalized cell line license agreements with a number of companies to provide rights to Life Technologies’ proprietary CHO (Chinese hamster ovary) cell lines for the production of recombinant proteins used as therapeutic agents and vaccines.


Toxicity Assay

September 16, 2010 8:47 am | Product Releases | Comments

Bioo Scientific announced the availability of the MaxDiscovery Aspartate Transaminase (AST) and Lactate Dehydrogenase (LDH) Color Endpoint Assays which use a proprietary, innovative technology for visible detection of in vivo toxicity using only 5 µL of serum.


Forest Pays Out $313M in Levothroid And Celexa Cases

September 16, 2010 8:41 am | by Pete Yost | News | Comments

Forest Pharmaceuticals Inc. has agreed to pay more than $313 million and plead guilty to obstruction of justice, distribution of the then-unapproved drug Levothroid and illegal promotion of Celexa for use in treating children and adolescents suffering from depression.


FDA Split on Meridia Withdrawal

September 16, 2010 8:38 am | News | Comments

Federal health advisers delivered a split opinion on whether to withdraw the diet pill Meridia due to evidence that it increases heart attack and stroke, with half voting to ban it and the others favoring new warnings and restricted distribution.


Cancer Researchers Find Step to Immortal Cells

September 16, 2010 8:34 am | News | Comments

Cancer Research UK scientists have uncovered a new strategy that could be used by cancer cells to side step the body’s normal safety checks and become immortal – a key step for a cancer cell.


Scientists Design Assay to Screen GOAT-Suppressing Drugs

September 16, 2010 8:25 am | News | Comments

Scientists at The Scripps Research Institute have designed a new molecular test that will allow researchers to look for potential drugs targeting a human metabolic enzyme believed to stimulate the appetite and play a role in diabetes.



September 16, 2010 8:21 am | by Rita C. Peters, Editorial Director | Articles | Comments

Way, way back when, in the very early days of my youth, singer/songwriter Carly Simon had a hit song, Anticipation. “We can never know about the days to come,” she sang. “But, we think about them, anyway.”

Single-cell Expression and Microfluidics

September 16, 2010 8:16 am | by Mike May, PhD; Contributing Editor | Articles | Comments

Research is showing that single cells differ in their expression even in tissues once considered homogenous. This could be especially useful knowledge in medical research.


Nabriva Antibiotic Safe for ABSSSI

September 16, 2010 8:04 am | News | Comments

Nabriva Therapeutics, a biotechnology company focused on developing a new class of antibiotics for serious infections caused by resistant pathogens, announced that a series of studies will be presented at the 50th ICAAC.


OXiGENE Drug Extends Survival Time

September 16, 2010 8:01 am | News | Comments

OXiGENE announced that positive results from a randomized, controlled, Phase 2/3 study of ZYBRESTAT (fosbretabulin, CA4P) were presented at the 14th International Thyroid Congress.


Forward Pharma Launches Psoriasis Drug Trial

September 16, 2010 7:57 am | News | Comments

Forward Pharma, A/S through its wholly owned German subsidiary Forward Pharma GmbH, announced initiation of its first phase 2 trial investigating efficacy and safety of different doses and regimes of FP187 in a double blind, placebo controlled trial.


Vical CMV Vaccines Protects Transplant Patients

September 16, 2010 7:53 am | News | Comments

Vical Incorporated announced the achievement of key efficacy, immunogenicity and safety results in a Phase 2 trial, establishing its TransVax cytomegalovirus vaccine as the first to provide evidence of protection in immunocompromised hematopoietic cell transplant recipients.



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.